Chimeric Antigen Receptor T-Cell Therapy - Living Drugs: Case Histories of Transformational Advances

Abstract

In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the development of CAR-T therapy, and 4) the situation in 2019.

Note: Funding Statement: Funding for this research was provided in part by Harvard Business School.

Declaration of Interests: We have no competing interests to report.